GENE Stock Overview
An exchange traded fund launched by UBS Fund Management (Luxembourg) S.A.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
UBS (Irl) ETF Public Limited Company - Global Gender Equality UCITS ETF Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF 16.01 |
52 Week High | CHF 16.42 |
52 Week Low | CHF 12.64 |
Beta | 0 |
11 Month Change | 0.88% |
3 Month Change | 4.91% |
1 Year Change | 26.63% |
33 Year Change | 21.67% |
5 Year Change | 56.76% |
Change since IPO | 77.69% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
GENE | GB Capital Markets | GB Market | |
---|---|---|---|
7D | -1.2% | -1.6% | -0.9% |
1Y | 26.6% | 33.6% | 11.7% |
Return vs Industry: GENE underperformed the UK Capital Markets industry which returned 33.6% over the past year.
Return vs Market: GENE exceeded the UK Market which returned 11.7% over the past year.
Price Volatility
GENE volatility | |
---|---|
GENE Average Weekly Movement | 1.4% |
Capital Markets Industry Average Movement | 3.9% |
Market Average Movement | 4.7% |
10% most volatile stocks in GB Market | 9.1% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: GENE has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: GENE's weekly volatility (1%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | n/a | n/a |
UBS (Irl) ETF Public Limited Company - Global Gender Equality UCITS ETF is an exchange traded fund launched by UBS Fund Management (Luxembourg) S.A. It is managed by UBS Asset Management (UK) Ltd. The fund invests in the public equity markets of developed countries across the globe.
UBS (Irl) ETF Public Limited Company - Global Gender Equality UCITS ETF Fundamentals Summary
GENE fundamental statistics | |
---|---|
Market cap | n/a |
Earnings (TTM) | UK£0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs GENE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GENE income statement (TTM) | |
---|---|
Revenue | UK£0 |
Cost of Revenue | UK£0 |
Gross Profit | UK£0 |
Other Expenses | UK£0 |
Earnings | UK£0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did GENE perform over the long term?
See historical performance and comparison